1
|
Walpot J, van Herck P, Collas V, Bossaerts L, Van de Heyning CM, Vandendriessche T, Heidbuchel H, Rodrigus I, De Block C, Small GR, Bosmans J. Adiponectin serum level is an independent and incremental predictor of all-cause mortality after transcatheter aortic valve replacement. Clin Cardiol 2022; 45:1060-1069. [PMID: 35932173 PMCID: PMC9574742 DOI: 10.1002/clc.23892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 06/20/2022] [Accepted: 07/12/2022] [Indexed: 11/22/2022] Open
Abstract
Background Quantifiable biomarkers may be useful for a better risk and frailty assessment of patients referred for transcatheter aortic valve implantation (TAVI). Hypothesis To determine if adiponectin serum concentration predicts all‐cause mortality in patients undergoing TAVI. Methods 77 consecutive patients, undergoing TAVI, were analyzed. The CT axial slices at the level of the fourth lumbar vertebra were used to measure the psoas muscle area, and its low‐density muscle fraction (LDM (%)). To assess the operative risk, the STS (Society of Thoracic Surgeons Predicted Risk of Mortality) score, Log. Euroscore, and Euroscore II were determined. A clinical frailty assessment was performed. ELISA kits were used to measure adiponectin serum levels. We searched for a correlation between serum adiponectin concentration and all‐cause mortality after TAVI. Results The mean age was 80.8 ± 7.4 years. All‐cause mortality occurred in 22 patients. The mean follow‐up was 1779 days (range: 1572–1825 days). Compared with patients with the lowest adiponectin level, patients in the third tertile had a hazards ratio of all‐cause mortality after TAVI of 4.155 (95% CI: 1.364–12.655) (p = .004). In the multivariable model, including STS score, vascular access of TAVI procedure, LDM (%), and adiponectin serum concentration, serum adiponectin level, and LDM(%) were independent predictors of all‐cause mortality after TAVI (p = .178, .303, .042, and .017, respectively). Adiponectin level was a predictor of all‐cause mortality in females and males (p = .012 and 0.024, respectively). Conclusion Adiponectin serum level is an independent and incremental predictor of all‐cause mortality in patients undergoing TAVI.
Collapse
Affiliation(s)
- Jeroen Walpot
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.,Department of Cardiology, ZorgSaam Hospital, Terneuzen, The Netherlands
| | - Paul van Herck
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium
| | - Valerie Collas
- Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
| | - Liene Bossaerts
- Faculty of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
| | - Caroline M Van de Heyning
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.,Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
| | - Tom Vandendriessche
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium
| | - Hein Heidbuchel
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.,Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
| | - Inez Rodrigus
- Department of Cardiac Surgery, University Hospital Antwerp, Antwerp, Edegem, Belgium
| | - Christophe De Block
- Department of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital, Edegem, Antwerp, Belgium
| | - Gary R Small
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Johan Bosmans
- Department of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.,Faculty of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
| |
Collapse
|